Reports Q4 revenue $207M, consensus $201.86M. “The year ahead marks an important turning point for the company, as we approach two potential product launches and a pivotal data readout that, together, could significantly accelerate our commercial revenue trajectory,” said Emil Kakkis, M.D., Ph.D., CEO of Ultragenyx (RARE). “We are implementing a strategic restructuring plan to reduce our operating expenses and ensure our resources are squarely aligned with our highest-impact opportunities, while leading the future of rare disease with multiple first ever treatments.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- RARE Upcoming Earnings Report: What to Expect?
- Ultragenyx: UX111 Progress, Regulatory De-Risking, and Pipeline Catalysts Support Attractive Risk/Reward and Buy Rating
- Ultragenyx Highlights New UX111 Data in FDA Resubmission
- Ultragenyx announces long-term data from studies evaluating UX111
- Ultragenyx: Advancing Rare Disease Pipeline, Key 2026–2027 Catalysts, and Path to Profitability Support Buy Rating